October 6, 2012
The Department of Defense officially terminated its contract with biotech company Sarepta (NASDAQ: SRPT ) for the development of an Ebola virus drug this week. While the company will continue to develop its Marburg virus drug under this contract, did the cancellation of this project have an effect on the company's share price? Didn't Sarepta have a stellar week after it released data related to its Duchenne's muscular dystrophy drug eteplirsen?
In the following video, health-care analysts Max Macaluso and David Williamson discuss this news and what investors should be watching at Sarepta going forward.
Sarepta's share price popped this week, but it wasn't The Motley Fool's Top Stock for 2012. To find out what it is before the rest of the market catches on, click here -- it's absolutely free.